Skip to main content
SpringerLink
Log in

Evidence-Based Use of Hematopoietic Growth Factors for Optimal Supportive Care of Patients with Cancer

  • Chapter
Oncology

Abstract

Hematopoiesis, the production and maintenance of blood elements, is critical to life. Many of the complications of cancer and anticancer therapies can be clinically damaging to patients as a result of adverse effects on normal hematopoietic mechanisms. Since the early 1990s, it has been possible for physicians to intervene with genetically engineered biotherapies, such as hematopoietic growth factors to mitigate the hematopoietic dysfunction of cancer patients. In this chapter, the evidence is examined upon which physicians and other caregivers may base rational clinical decision making to provide patients with optimal supportive care to improve the hematopoietic problems associated with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science 1985;229:16.

    Article  PubMed  CAS  Google Scholar 

  2. Morstyn G, Burgess AW. Hemopoietic growth factors: a review. Cancer Res 1988;48:5624.

    PubMed  CAS  Google Scholar 

  3. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (parts I and II). N Engl J Med 1992;327:28, 99.

    Article  PubMed  CAS  Google Scholar 

  4. Wingard JR, Demetri GD (eds). Clinical Applications of Cytokines and Growth Factors. Dordrecht: Kluwer, 1999.

    Google Scholar 

  5. Zoumbos NC, Gascon P, Djue J, et al. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med 1985;312:257.

    Article  PubMed  CAS  Google Scholar 

  6. Miller CB, Jones RJ, Piantadose S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689.

    Article  PubMed  CAS  Google Scholar 

  7. Hersh EM, Bodey GP, Niles BA, Freireich EJ. Causes of death in acute leukemia. A ten year study of 414 patients from 1954–1963. JAMA 1965;193:99.

    Google Scholar 

  8. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328.

    PubMed  CAS  Google Scholar 

  9. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316.

    PubMed  CAS  Google Scholar 

  10. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–3051.

    PubMed  CAS  Google Scholar 

  11. Chrischilles EA, Link BK, Scott SD, et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control 2003;10:396–403.

    PubMed  Google Scholar 

  12. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431–1439.

    Article  PubMed  CAS  Google Scholar 

  13. ASCO Ad Hoc Committee. American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Practice Guidelines. J Clin Oncol 1994;12:2471–2508.

    Google Scholar 

  14. ASCO Ad Hoc Committee. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidencebased, clinical practice guidelines. J Clin Oncol 1996;14:1957–1960.

    Google Scholar 

  15. ASCO Ad Hoc Committee. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1997;15:3288–3289.

    Google Scholar 

  16. Ozer H, Armitage JO, Bennett CL, et al. American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18(20):3558–3585.

    PubMed  CAS  Google Scholar 

  17. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907–1929.

    PubMed  CAS  Google Scholar 

  18. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454.

    Article  PubMed  CAS  Google Scholar 

  19. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809.

    PubMed  CAS  Google Scholar 

  20. Groopman JE, Mitsuyasu RT, DeLeo MJ, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987;317:593.

    Article  PubMed  CAS  Google Scholar 

  21. Antman K, Griffin J, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319:593.

    Article  PubMed  CAS  Google Scholar 

  22. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667.

    Article  PubMed  CAS  Google Scholar 

  23. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414.

    Article  PubMed  CAS  Google Scholar 

  24. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164.

    Article  PubMed  CAS  Google Scholar 

  25. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319.

    Article  PubMed  CAS  Google Scholar 

  26. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406–411.

    Article  PubMed  CAS  Google Scholar 

  27. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727–731.

    Article  PubMed  CAS  Google Scholar 

  28. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.

    Article  PubMed  CAS  Google Scholar 

  29. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178–1184.

    Article  PubMed  CAS  Google Scholar 

  30. Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 2003;21:1295–1313.

    Article  PubMed  Google Scholar 

  31. Komrokji RS, Lyman GH. Biological response modifiers used to prevent and treat neutropenia and its complications. Expert Opin Biol Ther 2004;4:1897–1910.

    Article  PubMed  CAS  Google Scholar 

  32. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [comment]. Clin Infect Dis 2002;34:730–751.

    Article  PubMed  Google Scholar 

  33. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205–1211.

    Article  PubMed  CAS  Google Scholar 

  34. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976–983.

    Article  PubMed  CAS  Google Scholar 

  35. Bennett CL, Stinson TJ, Laver JH, et al. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma 2000;37:65–70.

    PubMed  CAS  Google Scholar 

  36. Sung L, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3350–3356.

    Article  PubMed  CAS  Google Scholar 

  37. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colonystimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003;101:3862–3867.

    Article  PubMed  CAS  Google Scholar 

  38. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121(7):492–501.

    PubMed  CAS  Google Scholar 

  39. Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Systematic Review: CD 003039, 2004.

    Google Scholar 

  40. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181–188.

    Article  PubMed  CAS  Google Scholar 

  41. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997;336(25):1776–1780.

    Article  PubMed  CAS  Google Scholar 

  42. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002;39(2):89–94.

    Article  PubMed  CAS  Google Scholar 

  43. Lyman GH, Kuderer NM. The economics of the colonystimulating factors for the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–146.

    Article  PubMed  CAS  Google Scholar 

  44. Desai J, Demetri GD. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 2005;18(3):389–406.

    Article  PubMed  CAS  Google Scholar 

  45. Lee GR. The anemia of chronic disease. Semin Hematol 1983;20:61.

    PubMed  CAS  Google Scholar 

  46. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248–4267.

    PubMed  CAS  Google Scholar 

  47. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218–1234.

    PubMed  CAS  Google Scholar 

  48. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412–3425.

    PubMed  CAS  Google Scholar 

  49. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing, J Clin Oncol 2001;19:2875–2882.

    PubMed  CAS  Google Scholar 

  50. Vansteenkiste J, Pirker R, Massuti B. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94(16):1211–1220.

    PubMed  CAS  Google Scholar 

  51. Pirker R. Darbepoetin alfa for the treatment of cancer-related anemia: an update. Expert Rev Anticancer Ther 2004;4(5):735–744.

    Article  PubMed  CAS  Google Scholar 

  52. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9(6):696–707.

    Article  PubMed  CAS  Google Scholar 

  53. Finkelstein SN, Huber SL, Greenberg PE. Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997;31(9):1094–1095.

    PubMed  CAS  Google Scholar 

  54. Kurzrock R, Talpaz M, Estey E, et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1990;5:985.

    Google Scholar 

  55. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991;78:1658.

    PubMed  CAS  Google Scholar 

  56. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87(10):4076–4081.

    PubMed  CAS  Google Scholar 

  57. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99(2):344–351.

    Article  PubMed  CAS  Google Scholar 

  58. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351(14):1403–1408.

    Article  PubMed  CAS  Google Scholar 

  59. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  60. Hersh EM, Bodey GP, Niles BA, Freireich EJ. Causes of death in acute leukemia. A ten year study of 414 patients from 1954–1963. JAMA 1965;193:99.

    Google Scholar 

  61. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905.

    Article  PubMed  CAS  Google Scholar 

  62. Tepler I, Elias L, Smith JW II, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87(9):3607–3614.

    PubMed  CAS  Google Scholar 

  63. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100(10):3457–3469.

    Article  PubMed  CAS  Google Scholar 

  64. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241–3248.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarcoma Program, Dana-Farber Cancer Institute, Boston, MA, USA

    George D. Demetri MD (Clinical Director and Associate Professor)

  2. Department of Medicine, Harvard Medical School, Boston, MA, USA

    George D. Demetri MD (Clinical Director and Associate Professor)

Authors
  1. George D. Demetri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Demetri, G.D. (2006). Evidence-Based Use of Hematopoietic Growth Factors for Optimal Supportive Care of Patients with Cancer. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_87

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_87

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation